Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q2 & H1 FY25 Earnings Presentation
41 slides from Blue Jet Healthcare's earnings presentation, Nov 4, 2024
Slide 1: Revised Analysts/Investors Presentation filing letter
(is) BLUE JET HEALTHCARE LIMITED REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA, PLOT1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705 BLUE JET T : 022- 41840550 / 40037603 F : +91 22 27814204 HEALTHCARE E: sales@bluejethealthcare.com | CIN NO. : L99999MH1968PLC014154 November 4, 2024 BSE Li
Slide 2: Investor Presentation Q2 & H1 FY25
BLUE JET HEALTHCARE Investor Presentation Q2 &H1 FY25
Slide 3: Disclaimer
Disclaimer oJ" The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that a
Slide 4: Table of Content
@) BLUE JET HEALTHCARE Table of Content 1 Q2 & H1 FY25 Financials A Company at a Glance 3 Contrast Media Intermediates yA High Intensity Sweeteners 3) Pharma Intermediates & API 6) R&D Capabilities vi Growth Strategy 8 Management and Board of Directors =) Investment Rationale
Slide 5: Q2 & H1 FY25 Financials
q| Q2 &H1 FY25 Financials
Slide 6: Q2 & H1 FY25 Earnings Highlights
Q2 & H1 FY25 Earnings Highlights Financial Highlights Q2 FY25 v Revenue from operations for Q2 FY25 stood at Rs. 2,083 mn which grew 27.8% QoQ compared to Rs. 1,629 mn in Q1 FY25 ; up 14.8% on YoY basis compared to Rs. 1,814 mn in Q2 FY24. v Improved Profitability on QoQ basis was due to the change
Slide 7: Q2 & H1 FY25 Earnings Highlights
Q2 & H1 FY25 Earnings Highlights Financial Highlights H1 FY25 v Revenue from operations for H1 FY25 stood at Rs. 3,712 mn compared to Rs. 3,609 mn in H1 FY24, up 2.8% YoY EBITDA for H1 FY25 came at Rs. 1,138 mn down 6.4% YoY compared to Rs. 1,216 mn in H1 FY24.Compressed EBIDTA was mainly driven by
Slide 8: Q2 & H1 FY25 Earnings Highlights: Other Highlights
Q2 & H1 FY25 Earnings Highlights Other Highlights ¥ Maiden dividend payout completion Rs. 1 (50%) per share amounting to Rs. 173.5 Mn. ¥ Commercial dispatches of pharma intermediate product started from new plant no. 6 at Ambernath from end of September 2024. Y Inthe Artificial Sweetener space, comp
Slide 9: Q2 FY25 Vs Q2 FY24 Financial Performance — Key Metrics
Q2 FY25 Vs Q2 FY24 Financial Performance — Key Metrics oJ" Revenue from Operations—Growth Trends [avy YoY ee (11.1%) 171.9% Ly AL MQ2FY24 #8 Q2FY25 2,071 1,806 1,276 1,134 293 316 296 ie 18 25 mm a Contrast media intermediates High-intensitysweetners Pharma intermediates and API Others* Total . . mE
Slide 10: H1 FY25 Vs H1 FY24 Financial Performance — Key Metrics
H1 FY25 Vs H1 FY24 Financial Performance — Key Metrics Revenue from Operations — Growth Trends (Rs Mn) YoY crowthe - RR te) o 0 281.9% 0 eA 0 MHI1FY24 wWH1FY25 3,592 3,689 2,562 1,779 1,198 695 666 314 | Contrast media intermediates High-intensitysweetners Pharma intermediates and API Others* Total
Slide 11: Profit and Loss Statement
Profit and Loss Statement oJ" Particulars (Rs. Mn) Q2 FY25 Q1FY25 Q2FY24 YoY H1 FY25 H1 FY24 Revenue from Operations 2,083 1,629 27.8% 1,814 14.8% 3,712 3,609 2.8% Cost Of Goods Sold 895 738 783 1,633 1,576 Gross Profit 1,187 891 33.3% 1030 15.3% 2,078 2,033 2.2% Gross Margin 57.0% 54.7% 56.8% 56.0%
Slide 12: Financial Performance over the years — Key Metrics
Financial Performance over the years — Key Metrics J Revenue from Operations — Growth Trends (Rs Mn) CAGR: Ar ey yw ieee 6,768 7,084) 4,778 9:00 4,799 4,942 3,536 ,689 1,779 1 575 1,759 28 987 ” , 947 }1,198 al on 666 ale Gia Sahn 133 3 16 55 | 46 Es es Contrast media intermediates High-intensity sw
Slide 13: Financials for the last four years
Financials for the last four years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities Particulars (Rs. Mn) i 72 i PX) FY24| H1FY25 Particulars (Rs. Mn) FY21 FY22 FY23 FY24 H1FY25 Il. Assets Revenue from Operations 4,989 6,835 7,210 7,116 3,712 Property, plant and equipm
Slide 14: Shareholder Information
Shareholder Information Shareholding as on 30" September 2024 Share Information as on 30 September 2024 NSE Ticker BLUEJET Si ME Others BSE Ticker 544009 Other Dils 1.1% 9.8% Market Cap (INR Cr) 8.808 Fil % free-float 14% 2.0% Free-float market cap (INR Cr) 1,233 Cash & Cash Equivalents + Treasury 3
Slide 15: Company at a Glance
@ Company ata Glance 14
Slide 16: Our Journey
Our Journey ¢ Established Jet Chemicals ¢ Began manufacturing high- ¢ Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit |) saccharin and its salts building block (5- NIPA ) 1968 oN Commenced semi- automated ~€ . block f trast medi
Slide 17: Who we are
Who we are <e A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration Development, Manufacturing” to CDMO business.
Slide 18: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance J ( 46: ) ( 1,020.90 kL ) ( INR 7,115.99 mn INR 2,292.30 mn Commercialized product reaction capacity across Revenue (FY24) (12.6% EBITDA (FY24) (32.2% portfolio (FY24) 3 facilities (FY24) FY21-24 CAGR) margin) Key metrics ( 26.01% ROCE (FY23) ) ( 21.45% ROE (FY24) ) (
Slide 19: Overview of our Product Categories
Overview of our Product Categories Contrast Media maaan e adh aN Pharma Intermediates Intermediates Sweeteners & APIs = Contrast media are agents used in medical @ High-intensity sweetener business involves @ Collaboration with innovator pharmaceutical companies and multi-national generic imaging to
Slide 20: Contrast Media Intermediates
22 Contrast Media Intermediates is)
Slide 21: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers oJ" What is contrast media? Types of contrast media ™ Chemical agents that enhances the contrast of an imaging @ X-ray / Computed Tomography (CT) contrast agents: lodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast medi
Slide 22: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Highly concentrated and dominated by multi-national corporations Player 1 Others 17% 25% Total value US$5.9bn Collectively hold ~75% of the global sales of contrast (MAT Jun 2023) media formulations’ Player 3 27% Either forward integrated (ha
Slide 23: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors Y More than two decades of experience CAGR: 10.7% VY 75%+ of exports of a selected contrast media Strict internal standards intermediate (5-Amino-N,N'-bis (2,3- Revenue (INR mn) for product impurity / dihydroxypropyl) isophthalamide) from India’ v S
Slide 24: Continue to forward integrate into more advanced intermediates for Contrast Media
Continue to forward integrate into more advanced intermediates for @) Contrast Media Strong product development and process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in
Slide 25: High Intensity Sweeteners
/A\, High Intensity Sweeteners 24
Slide 26: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Products ] ” 4 a Adherence to strict internal standards to ensure consistency in quality, performance, | ONS ERSRA > Q) taste, and impurity profile Revenue (INR mn) Multip
Slide 27: Pharma Intermediates & API
LE Pharma Intermediates & API 26
Slide 28: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product (J) . Category | Key trends in Pharma Intermediates and CDMO market s Revenue and capacity utilization predictability ( ieressed propensity to outsource manufacturing of intermediates & APIs for the CDMO Enables asset light model and a
Slide 29: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product ©) . Category ; ; ; Pharma Intermediate and APIs Commenced manufacturing pharma intermediates two decades ere F ago, leveraging the customer relationships through high-intensity sd debebhaired Sua A hada beldietad sweetener business Key fo
Slide 30: Leverage long-standing customer relationships to enter adjacencies in pharma intermediates and API
Leverage our long-standing customer relationships to continue ©) . entering adjacencies in the pharma intermediate and API category , Focus on three niche areas in providing CDMO services "rm © Investigational new drugs and new chemical (Ss) Leverage long-standing relationships with innovator entiti
Slide 31: R&D Capabilities
(ES R&D Capabilities
Slide 32: Our R&D framework
Our R&D framework R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research ( ) ( Method ) ( Characterization of ) ( Polymorphism ) ( Pharmaceutical salt | ( ) ( High press
Slide 33: Sustainability
Sustainability Invested in windmills with installed capacity of 3.3MW pu a i Created carbon sinks Focus on enhancing through tree plantations energy efficiency — CTT mt —— TTT Effluent treatment plants with Minimizing solvents and modern standards of flocculation, using recycled solvents clarificati
Slide 34: Growth Strategy
7) Growth Strategy
Slide 35: Our strategies
Our strategies oJ" Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to invest in R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity customer
Slide 36: Management and Board of Directors
(Q) Management and Board of Directors 35
Slide 37: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - oard of Directors IM FeVatee<eVant-vanmxerelag Akshay Bansarilal Shiven Akshay Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President - Research
Slide 38: Experienced and visionary management team backed by independent Board of Directors (cont'd)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors Sweta Poddar Girish Paman Preeti Gautam Divya Sameer Company Secretary and Vanvari Mehta Momaya Compliance Officer Independent Director Independent Dire
Slide 39: Investment Rationale
(©) Investment Rationale 38
Slide 40: Investment Rationale
Investment Rationale oJ" Large manufacturer of contrast Presence in niche categories media intermediates in India with high barriers to entry Long-standing relationships and Strong product development and multi-year contracts with multi- process optimization capabilities national customers with a fo
Slide 41: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLU
Blue Jet Healthcare — Q2 & H1 FY25 Earnings Presentation on 6ix